MedPath

University of Pennsylvania

University of Pennsylvania logo
🇺🇸United States
Ownership
Private
Established
1740-11-14
Employees
5K
Market Cap
-
Website
http://www.upenn.edu

COVID-19 Vaccination Reduces Severe Kidney Damage Risk in Hospitalized Patients, UCLA Study Finds

UCLA Health researchers analyzed 3,500 hospitalized COVID-19 patients and found unvaccinated individuals were 16% more likely to require continuous renal replacement therapy during hospitalization.

Northwest Biotherapeutics to Present Next-Generation Dendritic Cell Therapy Advances at Cancer Immunotherapy Conference

Northwest Biotherapeutics' Chief Technical Officer Dr. Marnix Bosch will present on "supercharged" dendritic cells with enhanced anti-tumor effects at the Frontiers in Cancer Immunotherapy Conference on June 16.

IL-12-Modified mRNA Vaccines Demonstrate Enhanced T Cell Activation in University of Pennsylvania Study

Researchers from the University of Pennsylvania, including the School of Veterinary Medicine, Perelman School of Medicine, and Children's Hospital of Philadelphia, have developed modified mRNA vaccines incorporating cytokine IL-12 that significantly enhance CD8+ T cell responses.

Kennedy Pledges Accelerated FDA Approvals for Rare Disease Therapies to Maintain US Biotech Leadership

Health Secretary Robert F. Kennedy Jr. announced plans to fast-track FDA approvals for rare disease treatments and remove regulatory obstacles during a meeting focused on cell and gene therapies.

Researchers Unveil New Strategies to Harness Tumor Microenvironment for Enhanced Cancer Immunotherapy

Researchers at the 2025 ASCO Annual Meeting revealed how the tumor microenvironment's complex balance of pro-tumor and anti-tumor immune forces can be manipulated to improve immunotherapy responses.

Gilead's Dual-Target CAR-T Therapy Achieves 62% Response Rate in Recurrent Glioblastoma

Gilead Sciences' dual-target CAR-T therapy shrank tumors in 62% of patients with recurrent glioblastoma, a rare achievement for this fatal brain cancer.

Dual-Target CAR T Cell Therapy Achieves Tumor Shrinkage in 62% of Recurrent Glioblastoma Patients

A novel dual-target CAR T cell therapy targeting EGFR and IL13Rα2 proteins achieved tumor shrinkage in 62% of patients with recurrent glioblastoma, the most aggressive form of brain cancer.

Scientists Develop In Vivo CAR T-Cell Engineering to Reduce Cancer Treatment Costs and Complexity

Researchers at the University of Pennsylvania have successfully created CAR T-cell therapy directly inside the bodies of mice and monkeys, eliminating the need for expensive laboratory manufacturing processes.

Liv Hospital Partners with University of Pennsylvania to Establish Local CAR-T Cell Manufacturing in Turkey

Liv Hospital and Istinye University have signed a comprehensive collaboration with the University of Pennsylvania's Perelman School of Medicine to develop CAR-T cell therapy and proton therapy capabilities in Turkey.

Medicare Low-Income Drug Subsidy Loss Linked to Higher Mortality Rates

Loss of Medicare's Low-Income Subsidy (LIS) for prescription drugs following Medicaid disenrollment is associated with a 4% increase in mortality rates, according to a new study published in the New England Journal of Medicine.

© Copyright 2025. All Rights Reserved by MedPath